Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266902 | 0.96 | HTR7 (0.32) | HCRTR1HCRTR2CHRM3ALDH1A1HRH3 | |
| SCHEMBL1265699 | 0.93 | HTR7 (0.32) | HCRTR1HCRTR2CHRM3ALDH1A1MKNK1 | |
| SCHEMBL1265809 | 0.91 | MAPK14 (0.33) | HCRTR1HCRTR2CHRM3HRH3MKNK1 | |
| SCHEMBL1266917 | 0.86 | HCRTR1 (0.38) | HCRTR1HCRTR2CHRM3ALDH1A1HRH3 | |
| SCHEMBL1265841 | 0.86 | HCRTR1 (0.38) | HCRTR1HCRTR2CHRM3ALDH1A1HRH3 | |
| SCHEMBL1266932 | 0.86 | HCRTR1 (0.36) | HCRTR1HCRTR2CHRM3ALDH1A1TP53 | |
| SCHEMBL1266001 | 0.86 | HCRTR1 (0.36) | HCRTR1HCRTR2CHRM3ALDH1A1TP53 | |
| SCHEMBL1267018 | 0.85 | HRH3 (0.34) | ALDH1A1HRH3 | |
| SCHEMBL1266782 | 0.85 | MAPT (0.38) | HCRTR1HCRTR2ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL1266634 | 0.85 | HTR7 (0.33) | HCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | HCRTR1 3680/4885HCRTR2 3184/4885CHRM3 2882/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | HCRTR1 2830/4885HCRTR2 2381/4885CHRM3 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.